The phase I and IIb clinical trials of RMC-4630 (SHP2-inhibitor) plus LY3214996 (ERK-inhibitor) in patients with KRAS mutations in CRC, NSCLC, or PDAC are in progress (NCT04916236). Here, KRAS is linked to non-small cell lung carcinoma.